WO2004001069A3 - Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire - Google Patents

Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire Download PDF

Info

Publication number
WO2004001069A3
WO2004001069A3 PCT/FR2003/001910 FR0301910W WO2004001069A3 WO 2004001069 A3 WO2004001069 A3 WO 2004001069A3 FR 0301910 W FR0301910 W FR 0301910W WO 2004001069 A3 WO2004001069 A3 WO 2004001069A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
rtn3
gene
compositions
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/001910
Other languages
English (en)
Other versions
WO2004001069A2 (fr
Inventor
Luc Dupuis
Scala Franck Di
Tapia Marc De
Yves Larmet
Jean-Philippe Loeffler
De Aguilar Jose-Luis Gonzales
Anne Laurence Boutillier
Christian Gaiddon
Frederique Rene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Strasbourg
Original Assignee
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Strasbourg filed Critical Universite de Strasbourg
Priority to AU2003263250A priority Critical patent/AU2003263250A1/en
Publication of WO2004001069A2 publication Critical patent/WO2004001069A2/fr
Publication of WO2004001069A3 publication Critical patent/WO2004001069A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et des méthodes in vitro, ex vivo ou in vivo de diagnostic de pathologie affectant la transmission neuromusculaire, en particulier la sclérose latérale amyotrophique. La présente invention a trait plus spécifiquement à l'identification ou à la détection de l'expression du gène RTN3, permettant ainsi de diagnostiquer, de suivre l'évolution, éventuellement lors d'un traitement thérapeutique, d'un désordre lié à une affection neuromusculaire, telle que la sclérose latérale amyotrophique. Elle concerne également les différentes isoformes du gène RTN3, des sondes et des anticorps spécifiques de ces isoformes, et leur utilisation, notamment pour diagnostiquer, et/ou suivre l'évolution, éventuellement lors d'un traitement thérapeutique, d'un désordre lié à une affection neuromusculaire, telle que la sclérose latérale amyotrophique. Elle concerne également des procédés pour identifier, caractériser ou cribler des composés capables de moduler l'expression du gène RTN3, notamment l'expression de ses isoformes.
PCT/FR2003/001910 2002-06-25 2003-06-20 Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire Ceased WO2004001069A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003263250A AU2003263250A1 (en) 2002-06-25 2003-06-20 Compositions and methods for detecting pathologies affecting neuromuscular transmission

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/07846 2002-06-25
FR0207846A FR2841261B1 (fr) 2002-06-25 2002-06-25 Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire

Publications (2)

Publication Number Publication Date
WO2004001069A2 WO2004001069A2 (fr) 2003-12-31
WO2004001069A3 true WO2004001069A3 (fr) 2004-04-08

Family

ID=29720017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/001910 Ceased WO2004001069A2 (fr) 2002-06-25 2003-06-20 Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire

Country Status (3)

Country Link
AU (1) AU2003263250A1 (fr)
FR (1) FR2841261B1 (fr)
WO (1) WO2004001069A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039448A2 (fr) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 nouvelles proteines secretees
WO1999031236A2 (fr) * 1997-12-17 1999-06-24 Genset ADNc PROLONGES POUR PROTEINES SECRETEES
EP1067182A2 (fr) * 1999-07-08 2001-01-10 Helix Research Institute Proteine secretoire ou proteine de membrane
WO2001036631A1 (fr) * 1999-11-15 2001-05-25 Smithkline Beecham P.L.C. Polynucleotides et polypeptides humains nogo-c et leurs utilisations
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
US20020012965A1 (en) * 2000-01-12 2002-01-31 Strittmatter Stephen M. Nogo receptor-mediated blockade of axonal growth

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039448A2 (fr) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 nouvelles proteines secretees
WO1999031236A2 (fr) * 1997-12-17 1999-06-24 Genset ADNc PROLONGES POUR PROTEINES SECRETEES
EP1067182A2 (fr) * 1999-07-08 2001-01-10 Helix Research Institute Proteine secretoire ou proteine de membrane
WO2001036631A1 (fr) * 1999-11-15 2001-05-25 Smithkline Beecham P.L.C. Polynucleotides et polypeptides humains nogo-c et leurs utilisations
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US20020012965A1 (en) * 2000-01-12 2002-01-31 Strittmatter Stephen M. Nogo receptor-mediated blockade of axonal growth
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 13 February 2001 (2001-02-13), DRMANAC RT ET AL: "New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity", XP002265566, retrieved from EBI Database accession no. ABG29352 *
DATABASE EMBL [online] 13 February 2002 (2002-02-13), DRMANAC RT ET AL: "DNA encoding novel human diagnostic protein #29343", XP002265568, retrieved from EBI Database accession no. AAS93539 *
DATABASE EMBL [online] 13 September 1999 (1999-09-13), BOUGUELERET L ET AL: "New isolated human secreted proteins", XP002265565, retrieved from EBI Database accession no. AAY35980 *
DATABASE EMBL [online] 13 September 1999 (1999-09-13), BOUGUELERET L ET AL: "New isolated human secreted proteins", XP002265570, retrieved from EBI Database accession no. AAX97644 *
DATABASE EMBL [online] 22 January 2000 (2000-01-22), HATTORI M ET AL: "Homo sapiens 151,639 genomic DNA of 11q13", XP002265571, retrieved from EBI Database accession no. AP001193 *
DATABASE EMBL [online] 25 January 1999 (1999-01-25), "Human secreted protein encoded by gene 92 clone HAUBL57", XP002265569, retrieved from EBI Database accession no. AAW74963 *
DATABASE EMBL [online] 27 November 1999 (1999-11-27), HATTORI M ET AL: "Homosapiens genomic DNA", XP002265572, retrieved from EBI Database accession no. AP000753 *
DATABASE EMBL [online] 30 May 2001 (2001-05-30), OTA T ET AL: "Secretory protein or membrane protein", XP002265567, retrieved from EMI Database accession no. AX136396 *
IWAHASHI J ET AL: "Caenorhabditis elegans reticulon interacts with RME-1 during embryogenesis", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 293, May 2002 (2002-05-01), pages 698 - 704, XP002233930 *
MOREIRA E ET AL: "Cloning of a novel member of the reticulon gene family (RTN3): Gene structure and chromosal localization to 11q13", GENOMICS, vol. 58, 1999, pages 73 - 81, XP002233929 *

Also Published As

Publication number Publication date
FR2841261A1 (fr) 2003-12-26
AU2003263250A1 (en) 2004-01-06
AU2003263250A8 (en) 2004-01-06
FR2841261B1 (fr) 2004-08-27
WO2004001069A2 (fr) 2003-12-31

Similar Documents

Publication Publication Date Title
WO2007149985A3 (fr) Systemès et procédés pour analyser et évaluer la démence et des troubles de type démence.
WO2002040634A3 (fr) Minireseaux d'expression et leurs utilisations
CY1109062T1 (el) Μεθοδοι ανιχνευσεως και αναστολης της αγγειογενεσεως
EP1913388A4 (fr) Methodes et compositions pour le diagnostic et la surveillance d'une maladie cardiovasculaire atherosclereuse
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
EP2546649A3 (fr) Biomarqueurs de la stéatose hépatique et procédés les utilisant
EP2032716A4 (fr) Biomarqueurs de detection et de diagnostic d'epithelioma malpighien spinocellulaire de la tete et du cou
WO2008069975A3 (fr) Procédés d'utilisation de f-spondine en tant que biomarqueur pour des pathologies dégénératives des cartilages
WO2004065576A3 (fr) Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603,
WO1999016888A3 (fr) Polypeptides, polynucleotides et agents de modulation de sphingosine-1-phosphate lyase, et procedes d'utilisation de ceux-ci
EP1547996A4 (fr) Sondes de diagnostic et remedes contre des maladies presentant une accumulation de la proteine du prion et methode de marquage
WO2001053871A3 (fr) Inspection et echantillonnage in vivo d'un tissu
EP1583504A4 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
WO2004046729A3 (fr) Marqueurs a base de fluide corporel pour l'hypoxie tissulaire
EP1572091A4 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2008055491A3 (fr) Diagnostic et stratification des risques de diabète sucré par mr-proadm
WO2003065006A3 (fr) Procedes et compositions pour le traitement du cancer utilisant les molecules 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10
ATE384519T1 (de) Hemmer-darstellende mittel
WO2007146668A3 (fr) Utilisation d'imp3 en tant que marqueur pronostique de cancer
WO2004021008A3 (fr) Methodes de detection du cancer du sein et des ovaires
ATE451477T1 (de) Diagnose und überwachung von hepatozellulärem karzinom
EP1742654A4 (fr) Anticorps anti-lfl2 pour le diagnostic, le pronostic et le traitement d'un cancer
WO2004100998A3 (fr) Compositions et procedes de visualisation non effractive du beta-amyloide soluble
WO2008016385A3 (fr) Polypeptides désacylase, polynucléotides désacylase et leurs procédés d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP